Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9652W HIGH $12.30
Volume
5.20 K
Value Traded
62.59 K
Short % Float
-
-8.34%Week
-8.68%1 Month
-38.46%3 Month
-31.51%6 Month
-99.19%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.31 M
EPS (TTM)
-12.45
P/E Ratio
-
Ent. Value
-1.32 M
Total Shares
2.14 M
Float Shares
-
Insiders
-
Institutions
1.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CANF Catalyst Timeline
Dated clinical, regulatory and corporate events for Can-Fite Biopharma Ltd
Catalyst Timeline
Dated clinical, regulatory & corporate events for Can-Fite Biopharma Ltd
939Total events
19Upcoming
224Tier-1 (high impact)
2013 to 2044Coverage
Upcoming catalysts 2
Event history 50
▲PublicationNamodenosonPresentation
Peer-reviewed case report published in Japanese Journal of Gastroenterology and Hepatology on Namodenoson in decompensated cirrhosis
decompensated liver cirrhosissource ↗
▲Primary Endpoint MetNamodenosonClinical Data
Namodenoson Phase 2a pancreatic cancer study achieved primary safety endpoint
advanced pancreatic ductal adenocarcinomasource ↗
▲Enrollment CompletePiclidenosonFiledTrial
Enrollment completed of first 247 patients in pivotal Phase 3 Piclidenoson psoriasis study
moderate-to-severe plaque psoriasissource ↗
▲Patent GrantedNamodenosonIP / Competition
Patent allowances for novel therapeutic uses of Namodenoson across Israel, Canada, Brazil, Australia and Japan
▲Patent GrantedPiclidenosonFiledIP / Competition
Patent allowances for novel therapeutic uses of Piclidenoson across Israel, Canada, Brazil, Australia and Japan
▲Topline ReadoutNamodenosonClinical Data
Durable overall survival outcomes reported in Namodenoson Phase 2a pancreatic cancer study
advanced pancreatic ductal adenocarcinomasource ↗
▲Enrollment UpdateNamodenosonTrial
Blinded overall survival in pivotal Phase 3 HCC study appears longer than originally anticipated
advanced hepatocellular carcinomasource ↗
●Interim AnalysisPiclidenosonFiledTrial
Pivotal Phase 3 Piclidenoson psoriasis study reached pre-specified interim analysis stage
moderate-to-severe plaque psoriasissource ↗
▲Patent GrantedIP / Competition
Multiple patent allowances across Israel, Canada, Brazil, Australia and Japan for Namodenoson and Piclidenoson uses
▼Equity OfferingCorporate
Received approximately $4.0 million gross proceeds from warrant exercises and warrant inducement
▲Additional DataNamodenosonClinical Data
Case report: resolution of ascites and regression of esophageal varices with ~28 months clinical stability
decompensated liver cirrhosissource ↗
▲Preclinical PoCNamodenosonPreclinical
Preclinical findings show namodenoson enhances gemcitabine anti-cancer effect in pancreatic cancer
pancreatic cancersource ↗
●Trial InitiationPiclidenosonFiledTrial
Phase 2 clinical study protocol submitted to Bambino Gesù Children's Hospital for Piclidenoson in Lowe syndrome
Lowe syndromesource ↗
▲Partnership / LicensePiclidenosonFiledCorporate
Collaboration agreement with Fondazione Telethon for clinical development of Piclidenoson in Lowe syndrome
Lowe syndromesource ↗
▲Primary Endpoint MetNamodenosonClinical Data
Phase 2a study achieved primary safety endpoint
advanced pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Patent GrantedNamodenosonIP / Competition
Australian Patent Office allowed Patent Application No. 2021290439 for Namodenoson in advanced metastatic cancer
advanced metastatic cancersource ↗
▲Enrollment CompletePiclidenosonFiledTrial
Completed enrolment of first 247 patients in pivotal Phase 3 study for Piclidenoson
moderate-to-severe plaque psoriasissource ↗
◆Topline ReadoutPiclidenosonFiledClinical Data
Top-line results expected in Q3 2026
osteoarthritis in dogssource ↗
◆Topline ReadoutNamodenosonClinical Data
Top-line efficacy data expected in Q3 2026
pancreatic cancersource ↗
▲PublicationPresentation
Peer-reviewed article published on A3AR agonists Piclidenoson and Namodenoson in Biomolecules Journal
◆Topline ReadoutPiclidenosonFiledClinical Data
Piclidenoson Phase 3 topline results reported for psoriasis
psoriasissource ↗
▲Trial InitiationPiclidenosonFiledTrial
Piclidenoson pivotal Phase 3 trial commenced for psoriasis
psoriasissource ↗
◆Trial InitiationNamodenosonTrial
Namodenoson Phase IIb study ongoing for pancreatic cancer
pancreatic cancersource ↗
▲Enrollment CompleteNamodenosonTrial
Enrollment completed in Phase 2a pancreatic cancer study of namodenoson
pancreatic cancersource ↗
◆Oral PresentationNamodenosonPresentation
Phase 2b study design to be discussed at BIO International Convention
advanced pancreatic cancersource ↗
▲PublicationPiclidenosonFiledPresentation
Publication of peer-reviewed article on Piclidenoson for canine osteoarthritis in Frontiers in Veterinary Science
canine osteoarthritissource ↗
▲Topline ReadoutNamodenosonClinical Data
Phase 2a topline data showed favorable safety and clinical activity
advanced pancreatic adenocarcinomasource ↗
▲Topline ReadoutNamodenosonClinical Data
Positive Phase 2a data with namodenoson in pancreatic cancer
pancreatic cancersource ↗
▲Primary Endpoint MetNamodenosonClinical Data
Primary safety endpoint met in Phase 2a pancreatic cancer study
pancreatic cancersource ↗
▲Enrollment CompleteNamodenosonTrial
Enrollment completed in Phase 2a pancreatic cancer study
pancreatic cancersource ↗
◆Topline ReadoutNamodenosonClinical Data
Data expected from Phase IIa pancreatic cancer study
pancreatic cancersource ↗
◆Interim AnalysisPiclidenosonFiledTrial
Interim analysis data expected from Phase III psoriasis study
psoriasissource ↗
▲Enrollment CompletePiclidenosonFiledTrial
Completed enrollment in Phase 2 osteoarthritis study in dogs
osteoarthritis in dogssource ↗
▲Partnership / LicensePiclidenosonFiledCorporate
Vetbiolix exercised option to enter full licensing agreement
osteoarthritis in dogssource ↗
▲Long Term DataNamodenosonClinical Data
Patient with advanced HCC reached >9 years overall survival with complete response
hepatocellular carcinomasource ↗
▲Patent GrantedNamodenosonIP / Competition
Israeli Patent Office allowed patent application covering Namodenoson for fat loss and obesity
obesitysource ↗
▲Equity OfferingCorporate
Warrant exercises and warrant inducement raised ~$4.3M gross proceeds
▲Primary Endpoint MetNamodenosonClinical Data
Phase 2a study met primary safety endpoint
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲PublicationNamodenosonPresentation
Publication of anti-obesity effect of namodenoson in International Journal of Obesity
obesitysource ↗
▲Patent GrantedNamodenosonIP / Competition
Canadian Patent Office issued notice of allowance for patent covering Namodenoson for fat loss
anti-obesitysource ↗
▲Full ResultsNamodenosonClinical Data
Patient with decompensated liver cirrhosis successfully underwent liver transplantation after Namodenoson treatment
decompensated liver cirrhosissource ↗
▲Enrollment CompleteNamodenosonTrial
Patient enrollment completed in Phase 2a pancreatic cancer study of Namodenoson
pancreatic cancersource ↗
▼Reverse Stock SplitCorporate
1-for-3,000 reverse split of ordinary shares and ADS ratio change
●IND SubmissionPiclidenosonFiledIND
Plan to submit Phase II study protocol to regulatory authorities in Italy and EMA
Lowe Syndromesource ↗
▲Poster PresentationNamodenosonPresentation
Abstract on Namodenoson pancreatic cancer results accepted for poster at ESMO Congress 2026
advanced pancreatic ductal adenocarcinomasource ↗
Past FDA Catalysts and PDUFA Decisions
How CANF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Piclidenoson | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C54 / 100
Pipeline Score
$53M
Pipeline Value
Undervalued
Valuation Signal
4
Drugs Scored
11.3x
rNPV / MCap
Top 12%
Micro Cap(rank 80 of 658)
Percentile Rank
Can-Fite Biopharma Ltd carries a moderate pipeline score (54/100), with $4.2B risk-adjusted pipeline value, led by CF101 in Plaque Psoriasis (Phase 3), across $96B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Piclidenoson Small moleculeNCT06643260 | Plaque Psoriasis | Phase 3 | NOT YET_RECRUITING | 705 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every CANF program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Namodenoson Fast TrackOrphan | advanced hepatocellular carcinoma | Phase 3 | 2026-09-08 | longer-than-anticipated overall survivalRead More | Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CANF
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CANF for Q2 2026. | ||||
CANF Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CANF ranks across every disease it competes in
Competitive Position is a premium feature
See how CANF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCANF News
CANFCan-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Can-Fite BioPharma announced a peer-reviewed case report detailing a patient with advanced decompensated liver cirrhosis who experienced significant clinical improvements while treated with Namodenoson. The patient achieved resolution of ascites and regression of esophageal varices, ultimately leading to successful liver transplantation after 28 months. These findings suggest Namodenoson may be a promising therapeutic approach for advanced liver disease.
Read more →CANFCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Can-Fite BioPharma reported positive clinical updates and financial results for H1 2026. The ongoing Phase III study of Namodenoson in liver cancer shows longer-than-expected overall survival. Additionally, the Phase IIa study in pancreatic cancer achieved its primary safety endpoint. The company is also advancing its pivotal Phase 3 study for psoriasis to an interim analysis stage.
Read more →CANF▼ -28.3%on this newsshared move
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd. has announced the immediate exercise of warrants for approximately $4.0 million. The exercise involves 1,591,738 American Depositary Shares at a reduced price of $2.50 per share. The proceeds will be used for research, development, and general corporate purposes. The company is also issuing new warrants for additional ADSs.
Read more →CANF▼ -28.3%on this newsshared move
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Can-Fite BioPharma announced that the overall survival in its Phase III study of Namodenoson for advanced hepatocellular carcinoma is longer than expected. The company plans to conduct an interim analysis earlier than scheduled to assess survival outcomes between treatment groups. However, the study remains blinded, preventing definitive conclusions about efficacy.
Read more →CANF▲ +5.3%on this news
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Can-Fite BioPharma announced new preclinical findings indicating that namodenoson enhances the anti-cancer effects of gemcitabine chemotherapy in pancreatic cancer. These results support the design of a planned Phase IIb study, which will evaluate namodenoson in combination with gemcitabine and Nab-paclitaxel. The findings suggest that namodenoson increases tumor cell death by weakening cancer cell survival mechanisms.
Read more →CANFCan-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Can-Fite BioPharma has provided an update on its lead drug candidates, Namodenoson and Piclidenoson, both advancing in Phase III clinical trials. Namodenoson is being evaluated for advanced liver cancer, while Piclidenoson targets moderate-to-severe plaque psoriasis. The company has received FDA Fast Track and Orphan Drug designations for Namodenoson, enhancing its regulatory position.
Read more →CANFCan-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Can-Fite BioPharma has submitted a Phase 2 clinical study protocol for Piclidenoson targeting Lowe syndrome, a rare genetic disorder. The study aims to evaluate the drug's efficacy and safety in adult patients. This initiative marks a significant milestone for Can-Fite, as it seeks to address a critical unmet medical need in this patient population.
Read more →CANFCan-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Can-Fite BioPharma announced that its Phase 2a study results for Namodenoson in advanced pancreatic cancer have been accepted for presentation at the ESMO Congress 2026. The study demonstrated durable disease stabilization and positive survival outcomes in patients who had previously undergone standard therapies. This recognition underscores the potential of Namodenoson as a treatment option in this challenging patient population.
Read more →CANFCan-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Can-Fite BioPharma has received an allowance for an Australian patent supporting the development of Namodenoson for liver and pancreatic cancers. The drug is currently in pivotal Phase 3 trials for hepatocellular carcinoma and has shown positive results in Phase 2a studies for pancreatic cancer. The patent enhances Can-Fite's global market position and intellectual property.
Read more →CANFCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite BioPharma has completed patient enrolment for its pivotal Phase 3 study of Piclidenoson, targeting moderate-to-severe plaque psoriasis. The study, which involves 247 patients, is set for an interim analysis under FDA and EMA protocols. Results are anticipated in Q4 2026 or Q1 2027, highlighting the drug's potential as an oral treatment option.
Read more →CANF▲ +55.9%on this newsshared move
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite BioPharma's Phase 2a study of Namodenoson in advanced pancreatic cancer has achieved its primary safety endpoint and shown promising survival outcomes. The study involved 20 patients, with significant survival rates observed in those treated with Namodenoson. The company plans to further investigate the drug in a Phase 2b study in combination with chemotherapy.
Read more →CANF▼ -6.5%on this news· ran to +57% by day 3shared move
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite BioPharma has received a patent allowance in Japan for its drug Namodenoson, aimed at treating obesity and metabolic disorders. This patent strengthens the company's intellectual property portfolio, which already includes protections in major markets. Namodenoson's unique mechanism of action and established safety profile position it favorably in the expanding obesity therapeutics market.
Read more →CANFCan-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite BioPharma Ltd. announced the publication of a peer-reviewed article highlighting the therapeutic potential of its drug candidates, Piclidenoson and Namodenoson. The article reviews evidence from various research groups, demonstrating the efficacy of A3 adenosine receptor agonists in treating multiple diseases. This publication underscores Can-Fite's strategy to leverage A3AR agonists for diverse therapeutic applications.
Read more →CANFCan-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite BioPharma will present its late-stage clinical pipeline at the BIO International Convention 2026 in San Diego. The company aims to engage in partnering meetings to explore licensing and commercialization opportunities for its drug candidates, including Namodenoson and Piclidenoson, which are in pivotal Phase III studies. The event is crucial for Can-Fite to establish strategic collaborations in oncology and inflammatory diseases.
Read more →CANFCan-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
Can-Fite BioPharma has reported positive clinical observations from its Phase 2a study of namodenoson in pancreatic cancer, highlighting its ability to inhibit the RAS signaling pathway. The study has shown prolonged disease control in several patients, including one who has been on therapy for approximately 16 months. Namodenoson is noted for its multi-pathway mechanism and favorable safety profile.
Read more →CANFScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Can-Fite BioPharma announced the publication of positive findings regarding Piclidenoson for treating canine osteoarthritis in the journal Frontiers in Veterinary Science. The study demonstrated significant improvements in mobility and pain assessments in dogs, supporting its development as a disease-modifying therapy. Vetbiolix, under a licensing agreement with Can-Fite, is progressing with advanced clinical studies of Piclidenoson, which represents a considerable commercial opportunity in the veterinary market, estimated to be worth billions.
Read more →CANF▲ +7.4%on this newsshared move
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Can-Fite BioPharma is advancing its pancreatic cancer program into a Phase 2b study of Namodenoson in combination with immunotherapy, following positive results from a Phase 2a trial. The Phase 2a study showed a favorable safety profile and clinical activity, with some patients on treatment for over 16 months. The company plans to discuss the study design at the BIO International Convention while exploring partnerships with oncology firms.
Read more →CANF▲ +6.7%on this news
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Can-Fite BioPharma Ltd. announced positive results from its Phase 2a study of namodenoson for advanced pancreatic cancer, showing clinical activity and a favorable safety profile. Key findings included stable disease in over 30% of evaluable patients and 35% remaining on therapy, with one individual extending treatment beyond 16 months. The trial suggests namodenoson may offer durable benefits in this challenging patient population. Full efficacy analyses and additional results are anticipated in the coming months.
Read more →CANFANNUAL GENERAL MEETING OF SHAREHOLDERS BE HELD ON MAY 28, 2026
Can-Fite BioPharma Ltd. has announced its 2026 Annual General Meeting (AGM) scheduled for May 28, 2026. The agenda includes re-electing a board member, increasing authorized share capital, granting options to key executives, and appointing an auditing firm. Shareholders are encouraged to attend and vote on the proposals. The announcement aims to inform and invite participation in important company decisions.
Read more →CANFCan-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite BioPharma's partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for treating osteoarthritis in dogs. The study involves 118 dogs and aims to assess symptom severity and mobility over 90 days. Top-line results are anticipated in Q3 2026, with potential revenues of up to $325 million from the licensing agreement with Vetbiolix.
Read more →About Can-Fite Biopharma Ltd
Headquarters26 Ben Gurion Street, Ramat Gan, 5257346, Israel
BIOPHARMAWATCH ELITE PLUS
Trade the next CANF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime